
BGI Genomics
BGI Genomics is one of the world’s largest DNA sequencing service providers.
BGI Genomics, founded in August, 2008 and headquartered in Shenzhen, is a genomics R&D institution. The founder is Wang Jian. Listed on the SZSE on July 14, 2017, the company's major shareholders are BGI Genomics Co.,Ltd., Shenzhen Qianhai BGI Investment Enterprise (LP) and Shenzhen Heyu Gaolin Equity Investment Partnership (LP). Rivals that have direct and indirect competition with BGI Genomics include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
JPMorgan Chase: CSI 300 index is expected to reach an all-time high in the next 12 months
Guanglian Airlines: it plans to acquire 51% equity of Hangsheng Aviation Machinery Co., Ltd. for 35.87 million yuan
BGI: thalassemia gene testing products have been approved by SFDA for listing
Tianneng heavy industry: in order to further promote the expansion of the company's industrial chain, it plans to set up a subsidiary in Hong Kong
Antiviral stocks rose in the afternoon
Open Source, Open Mind: Baidu and LinkingMed Help Doctors in Medical Images
A Chinese startup, based on Baidu’s deep-learning open-source platform PaddlePaddle, is providing CT screening service to a Hunan-based hospital, hoping to facilitate the diagnosis process.
Mar 05, 2020 11:41 AM
Su'ao sensor: the shareholding ratio of Wang Wenqiao, the shareholder, was passively diluted to 1.1%
Jinlang Technology: sign contract to purchase IGBT and other electronic components
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening